Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Lawrence Brody, George Weinstock

Premium

The National Human Genome Research Institute has appointed Lawrence Brody as director of the newly established Division of Genomics and Society. He is currently chief of the Genome Technology branch within NHGRI's intramural research program and CSO of the trans-NIH Center for Inherited Disease Research. He holds a BS from Pennsylvania State University and a PhD from Johns Hopkins University.


George Weinstock has joined the Jackson Laboratory as a professor and associate director for microbial genomics. He is currently a leader of the Human Microbiome Project. Weinstock joins the Jackson Laboratory from the Genome Institute at Washington University, where he was an associate director. Previously, he was co-director of the Human Genome Sequencing Center at Baylor College of Medicine and a professor in the department of human and molecular genetics. He holds a BS from the University of Michigan and a PhD from MIT.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.